Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto, Nuria Valdés-Sanz, Yoko Ogawa, Monica Alves, Luigi Berchicci, John Galvin, Hildegard Greinix, Gregory A. Hale, Biljana Horn, Debra Kelly, Hien Liu, Scott Rowley, Helene Schoemans, Ami Shah, Maria Teresa Lupo Stanghellini, Vaibhav Agrawal, Ibrahim Ahmed, Asim Ali, Neel Bhatt, Michael ByrneSaurabh Chhabra, Zack DeFilipp, Kristina Fahnehjelm, Nosha Farhadfar, Erich Horn, Catherine Lee, Sunita Nathan, Olaf Penack, Pinki Prasad, Seth Rotz, Alicia Rovó, Jean Yared, Steven Pavletic, Grzegorz W. Basak, Minoo Battiwalla, Rafael Duarte, Bipin N. Savani, Mary E.D. Flowers, Bronwen E. Shaw, Igor Petriček

Research output: Contribution to journalReview articlepeer-review

54 Citations (Scopus)

Abstract

Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Ocular GVHD has at least three biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have found several novel pathogenic mechanisms, including renin angiotensin system and endoplasmic reticulum stress signaling that can be targeted by therapeutic agents. Many studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. Efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD for optimal care.

Original languageEnglish
Pages (from-to)662-673
Number of pages12
JournalBone Marrow Transplantation
Volume54
Issue number5
DOIs
Publication statusPublished - 01-05-2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT'. Together they form a unique fingerprint.

Cite this